Insulin-like growth factor 1 (IGF-1) as a marker of cognitive decline in normal ageing: A review
Dopaminergic activity increases in ways that enhance motivation, focus, and reward processing without the dysregulation associated with stimulant drugs
During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide
pH and solution chemistry Reconstituted peptide stability depends heavily on solution pH
World Journal of Urology
Recalls & Warnings May 14, 2016 Xylitol in Supplements Poses Danger for Dogs On May 12, 2016, the FDA warned consumers that xylitol, a popular sweetener found in chewable vitamins, chewing gum, breath mints, toothpaste and a variety of other products, is toxic to dogs
